

Dean A Follmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9131276/publications.pdf>

Version: 2024-02-01

156
papers

21,603
citations

46918

47
h-index

10708

138
g-index

164
all docs

164
docs citations

164
times ranked

32463
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine efficacy at a point in time. <i>Biostatistics</i> , 2023, 24, 603-617.	0.9	5
2	A Note on Familywise Error Rate for a Primary and Secondary Endpoint. <i>Biometrics</i> , 2023, 79, 1114-1118.	0.8	0
3	Discussion on "estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian. <i>Biometrics</i> , 2022, 78, 844-847.	0.8	1
4	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
5	A mixture distribution approach for assessing genetic impact from twin study. <i>Statistics in Medicine</i> , 2022, , .	0.8	0
6	Risk Heterogeneity and the Illusion of Waning Vaccine Efficacy. <i>Annals of Internal Medicine</i> , 2022, 175, 444-445.	2.0	4
7	Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated. <i>Statistics in Medicine</i> , 2022, 41, 3076-3089.	0.8	3
8	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
9	A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 619-629.	13.9	741
10	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	2.0	86
11	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
12	Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	25
13	Coronavirus Occurrence in the Household Influenza Vaccine Evaluation (HIVE) Cohort of Michigan Households: Reinfection Frequency and Serologic Responses to Seasonal and Severe Acute Respiratory Syndrome Coronaviruses. <i>Journal of Infectious Diseases</i> , 2021, 224, 49-59.	1.9	26
14	Assessing vaccine durability in randomized trials following placebo crossover. <i>Statistics in Medicine</i> , 2021, 40, 5983-6007.	0.8	12
15	Comment. <i>Statistics in Medicine</i> , 2021, 40, 2526-2527.	0.8	2
16	How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 730-731.	2.0	0
17	The mechanistic analysis of founder virus data in challenge models. <i>Statistics in Medicine</i> , 2021, 40, 4492-4504.	0.8	2
18	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Joint testing of overall and simple effects for the two-by-two factorial trial design. <i>Clinical Trials</i> , 2021, 18, 521-528.	0.7	5
20	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
21	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
22	On Causal Inferences for Personalized Medicine: How Hidden Causal Assumptions Led to Erroneous Causal Claims About the D-Value. <i>American Statistician</i> , 2020, 74, 243-248.	0.9	3
23	Predictive cluster level surrogacy in the presence of interference. <i>Biostatistics</i> , 2020, 21, e33-e46.	0.9	1
24	Analysis of ordered composite endpoints. <i>Statistics in Medicine</i> , 2020, 39, 602-616.	0.8	13
25	A unified evaluation of differential vaccine efficacy. <i>Biometrics</i> , 2020, 76, 1053-1063.	0.8	1
26	Endpoints for randomized controlled clinical trials for COVID-19 treatments. <i>Clinical Trials</i> , 2020, 17, 472-482.	0.7	55
27	Post-treatment Lyme disease symptoms score: Developing a new tool for research. <i>PLoS ONE</i> , 2019, 14, e0225012.	1.1	10
28	Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms. <i>American Journal of Infection Control</i> , 2019, 47, 1040-1047.	1.1	8
29	A meta-analysis of clinical studies conducted during the West Africa Ebola virus disease outbreak confirms the need for randomized control groups. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	21
30	Tomorrow's HIV Prevention Trials of Vaccines and Antibodies. <i>Statistical Communications in Infectious Diseases</i> , 2019, 11, .	0.2	2
31	Half blind superiority tests for clinical trials of anti-infective drugs. <i>Statistics in Medicine</i> , 2019, 38, 31-43.	0.8	1
32	Sequential, Multiple-Assignment, Randomized Trials for Comparing Personalized Antibiotic Strategies (SMART-COMPASS). <i>Clinical Infectious Diseases</i> , 2019, 68, 1961-1967.	2.9	11
33	A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. <i>Nature Medicine</i> , 2018, 24, 610-616.	15.2	94
34	Streptococcal group A, C and G pharyngitis in school children: a prospective cohort study in Southern India. <i>Epidemiology and Infection</i> , 2018, 146, 848-853.	1.0	8
35	Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay. <i>Journal of Virological Methods</i> , 2018, 255, 84-90.	1.0	26
36	Sieve Analysis Using the Number of Infecting Pathogens. <i>Biometrics</i> , 2018, 74, 1023-1033.	0.8	4

#	ARTICLE	IF	CITATIONS
37	A boundary-optimized rejection region test for the two-sample binomial problem. <i>Statistics in Medicine</i> , 2018, 37, 1047-1058.	0.8	5
38	Conditional independence test by generalized Kendall's tau with generalized odds ratio. <i>Statistical Methods in Medical Research</i> , 2018, 27, 3224-3235.	0.7	4
39	Novel Superiority Tests for Anti-Infective Drug Trials: Three Examples. <i>Statistics in Biopharmaceutical Research</i> , 2018, 10, 9-17.	0.6	2
40	Semiparametric pseudoscore for regression with multidimensional but incompletely observed regressor. <i>Statistics in Medicine</i> , 2018, 37, 207-217.	0.8	0
41	Causal estimands and confidence intervals associated with Wilcoxon-Mann-Whitney tests in randomized experiments. <i>Statistics in Medicine</i> , 2018, 37, 2923-2937.	0.8	21
42	Reliably picking the best endpoint. <i>Statistics in Medicine</i> , 2018, 37, 4374-4385.	0.8	4
43	Response to letter by Antonio Martn Andrs on "A boundary-optimized rejection region test for the two-sample binomial problem". <i>Statistics in Medicine</i> , 2018, 37, 2303-2306.	0.8	0
44	Impact of Intravenous Immunoglobulin on Survival in Necrotizing Fasciitis with Vasopressor-dependent Shock: A Propensity-Score Matched Analysis from 130 US Hospitals. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw871.	2.9	65
45	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	13.9	199
46	Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the Evidence. <i>PLoS ONE</i> , 2016, 11, e0159727.	1.1	17
47	Who really gets strep sore throat? Confounding and effect modification of a time-varying exposure on recurrent events. <i>Statistics in Medicine</i> , 2016, 35, 4398-4412.	0.8	1
48	Non-inferiority tests for anti-infective drugs using control group quantiles. <i>Clinical Trials</i> , 2016, 13, 632-640.	0.7	2
49	Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit-Risk Evaluation. <i>Statistics in Biopharmaceutical Research</i> , 2016, 8, 386-393.	0.6	93
50	Reply to Phillips, Morris, and Walker. <i>Clinical Infectious Diseases</i> , 2016, 62, 815-816.	2.9	5
51	Augmented trial designs for evaluation of principal surrogates. <i>Biostatistics</i> , 2016, 17, 453-467.	0.9	7
52	Recurrent event data analysis with intermittently observed time-varying covariates. <i>Statistics in Medicine</i> , 2016, 35, 3049-3065.	0.8	8
53	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	0.7	63
54	Incorporating Founder Virus Information in Vaccine Field Trials. <i>Biometrics</i> , 2015, 71, 386-396.	0.8	8

#	ARTICLE	IF	CITATIONS
55	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	1.1	23
56	Comment: Fundamentals and Innovation in Antibiotic Trials. <i>Statistics in Biopharmaceutical Research</i> , 2015, 7, 331-336.	0.6	15
57	Vaccine design via nonnegative lasso-based variable selection. <i>Statistics in Medicine</i> , 2015, 34, 1791-1798.	0.8	6
58	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). <i>Clinical Infectious Diseases</i> , 2015, 61, 800-806.	2.9	206
59	Mycobacterial Antigen Driven Activation of CD14 ⁺ CD16 ⁺ Monocytes Is a Predictor of Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. <i>PLoS Pathogens</i> , 2014, 10, e1004433.	2.1	111
60	Matched Longitudinal Analysis of Biomarkers Associated with Survival. <i>Vaccine Journal</i> , 2014, 21, 1145-1152.	3.2	1
61	Estimating the burden of pertussis in Mexican adolescents from paired serological data by using a bivariate mixture model. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2014, 63, 621-637.	0.5	1
62	Estimation of mean response via the effective balancing score. <i>Biometrika</i> , 2014, 101, 613-624.	1.3	19
63	Semiparametric mixture survival model with application to MRFIT study. <i>Statistics and Its Interface</i> , 2014, 7, 19-26.	0.2	1
64	Discordant minimum inhibitory concentration analysis: A new path to licensure for anti-infective drugs. <i>Clinical Trials</i> , 2013, 10, 876-885.	0.7	9
65	A maximum pseudo-profile likelihood estimator for the Cox model under length-biased sampling. <i>Biometrika</i> , 2012, 99, 199-210.	1.3	25
66	Development of Functional and Molecular Correlates of Vaccine-Induced Protection for a Model Intracellular Pathogen, <i>F. tularensis</i> LVS. <i>PLoS Pathogens</i> , 2012, 8, e1002494.	2.1	50
67	Anthrax Vaccine-Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge. <i>Science Translational Medicine</i> , 2012, 4, 151ra126.	5.8	52
68	A valid formulation of the analysis of noninferiority trials under random effects meta-analysis. <i>Biostatistics</i> , 2012, 13, 637-649.	0.9	20
69	Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis. <i>New England Journal of Medicine</i> , 2012, 367, 1508-1518.	13.9	496
70	Semiparametric Double Balancing Score Estimation for Incomplete Data With Ignorable Missingness. <i>Journal of the American Statistical Association</i> , 2012, 107, 247-257.	1.8	10
71	A test of location for exchangeable multivariate normal data with unknown correlation. <i>Journal of Multivariate Analysis</i> , 2012, 104, 115-125.	0.5	0
72	Pre-ART Levels of Inflammation and Coagulation Markers Are Strong Predictors of Death in a South African Cohort with Advanced HIV Disease. <i>PLoS ONE</i> , 2012, 7, e24243.	1.1	89

#	ARTICLE	IF	CITATIONS
73	An Augmented Probit Model for Missing Predictable Covariates in Quantal Bioassay with Small Sample Size. <i>Biometrics</i> , 2011, 67, 1127-1134.	0.8	1
74	A hierarchical rank test for crossover trials with censored data. <i>Statistics in Medicine</i> , 2011, 30, 3507-3519.	0.8	2
75	Dimension reduced kernel estimation for distribution function with incomplete data. <i>Journal of Statistical Planning and Inference</i> , 2011, 141, 3084-3093.	0.4	8
76	A model checking method for the proportional hazards model with recurrent gap time data. <i>Biostatistics</i> , 2011, 12, 535-547.	0.9	9
77	High Dose Atorvastatin Decreases Cellular Markers of Immune Activation Without Affecting HIV-1 RNA Levels: Results of a Double-blind Randomized Placebo Controlled Clinical Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 756-764.	1.9	132
78	Design and Analysis of Crossover Trials for Absorbing Binary Endpoints. <i>Biometrics</i> , 2010, 66, 958-965.	0.8	33
79	Semiparametric dimension reduction estimation for mean response with missing data. <i>Biometrika</i> , 2010, 97, 305-319.	1.3	32
80	Interferon- γ Produces Significant Decreases in HIV Load. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 461-464.	0.5	37
81	Neutralizing Antibody Titers Conferring Protection to Macaques from a Simian/Human Immunodeficiency Virus Challenge Using the TZM-bl Assay. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 89-98.	0.5	40
82	Exact Inference for Complex Clustered Data Using Within-Cluster Resampling. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 850-869.	0.4	8
83	CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral Transmission. <i>Journal of Infectious Diseases</i> , 2010, 201, 178-185.	1.9	145
84	Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers. <i>Journal of Virology</i> , 2009, 83, 11857-11861.	1.5	62
85	Genetic Variation in OAS1 Is a Risk Factor for Initial Infection with West Nile Virus in Man. <i>PLoS Pathogens</i> , 2009, 5, e1000321.	2.1	213
86	Chopâ€Lump Tests for Vaccine Trials. <i>Biometrics</i> , 2009, 65, 885-893.	0.8	25
87	Cluster without fluster: The effect of correlated outcomes on inference in randomized clinical trials. <i>Statistics in Medicine</i> , 2008, 27, 795-809.	0.8	13
88	A nonparametric likelihood test for detecting discordance between two measurements with application to censored viral load determinations. <i>Statistics in Medicine</i> , 2008, 27, 4489-4501.	0.8	3
89	Dynamic Comparison of Kaplanâ€Meier Proportions: Monitoring a Randomized Clinical Trial with a Longâ€Term Binary Endpoint. <i>Biometrics</i> , 2008, 64, 189-197.	0.8	1
90	Contribution of TCR- β Locus and HLA to the Shape of the Mature Human $V\beta$ Repertoire. <i>Journal of Immunology</i> , 2008, 180, 6484-6489.	0.4	14

#	ARTICLE	IF	CITATIONS
91	Empirical Likelihood-Based Estimation of the Treatment Effect in a Pretest-Posttest Study. <i>Journal of the American Statistical Association</i> , 2008, 103, 1270-1280.	1.8	12
92	Lysis of Endogenously Infected CD4+ T Cell Blasts by rIL-2 Activated Autologous Natural Killer Cells from HIV-Infected Viremic Individuals. <i>PLoS Pathogens</i> , 2008, 4, e1000101.	2.1	88
93	HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19851-19856.	3.3	111
94	Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the Cox model. <i>Annals of Applied Statistics</i> , 2008, 2, 386-407.	0.5	32
95	Random effects and latent processes approaches for analyzing binary longitudinal data with missingness: a comparison of approaches using opiate clinical trial data. <i>Statistical Methods in Medical Research</i> , 2007, 16, 417-439.	0.7	19
96	Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5056-5061.	3.3	50
97	Statistical methods for active extension trials. <i>Statistics in Medicine</i> , 2007, 26, 2433-2448.	0.8	0
98	Accounting for Variability in Sample Size Estimation with Applications to Nonadherence and Estimation of Variance and Effect Size. <i>Biometrics</i> , 2007, 63, 465-474.	0.8	26
99	Augmented Designs to Assess Immune Response in Vaccine Trials. <i>Biometrics</i> , 2006, 62, 1161-1169.	0.8	96
100	Characterization of the defective interaction between a subset of natural killer cells and dendritic cells in HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2006, 203, 2339-2350.	4.2	162
101	Correlation between Immunologic Responses to a Recombinant Glycoprotein 120 Vaccine and Incidence of HIV-1 Infection in a Phase 3 HIV-1 Preventive Vaccine Trial. <i>Journal of Infectious Diseases</i> , 2005, 191, 666-677.	1.9	333
102	Analysis of the Human T Cell Receptor (TCR) Repertoire from Birth to Old Age Suggests That TCRV β frequencies Are Established Independent of HLA. <i>Blood</i> , 2005, 106, 3313-3313.	0.6	0
103	Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 125-30.	0.6	4
104	Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2004, 78, 10566-10573.	1.5	68
105	The Accelerated Biased Coin Up-and-Down Design in Phase I Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2004, 14, 249-260.	0.4	18
106	Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. <i>Blood</i> , 2004, 103, 4070-4077.	0.6	14
107	Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. <i>Blood</i> , 2004, 103, 3282-3286.	0.6	47
108	Analysis of Clonal Contributions to T Lymphoid and Myeloid Lineages during Early Hematopoiesis Following Autologous Transplantation in the Rhesus Macaque. <i>Blood</i> , 2004, 104, 2672-2672.	0.6	0

#	ARTICLE	IF	CITATIONS
109	The Spectrum of Human T Cell Receptor (TCR)- \hat{V} ² Frequencies Are Established Prior to Thymic Selection.. Blood, 2004, 104, 3240-3240.	0.6	0
110	Comparing HLA antigen frequencies between two groups of patients. Statistics in Medicine, 2003, 22, 1999-2013.	0.8	2
111	Multiple Outputation: Inference for Complex Clustered Data by Averaging Analyses from Independent Data. Biometrics, 2003, 59, 420-429.	0.8	96
112	A Random Effects Transition Model For Longitudinal Binary Data With Informative Missingness. Statistica Neerlandica, 2003, 57, 100-111.	0.9	32
113	The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. Journal of the American College of Cardiology, 2003, 42, 914-922.	1.2	198
114	A comparative analysis of the results from 4 trials of \hat{I} ² -blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. Journal of Cardiac Failure, 2003, 9, 354-363.	0.7	164
115	Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia. JAMA - Journal of the American Medical Association, 2003, 289, 1130.	3.8	353
116	T-cell large granular lymphocyte leukemia is characterized by massive TCRBV-restricted clonal CD8 expansion and a generalized overexpression of the effector cell marker CD57. The Hematology Journal, 2003, 4, 18-25.	2.0	31
117	Parametric and semiparametric approaches to testing for seasonal trend in serial count data. Biostatistics, 2002, 3, 289-298.	0.9	35
118	Intracellular interferon- \hat{I} ³ in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood, 2002, 100, 1185-1191.	0.6	187
119	Designing Monte Carlo Implementations of Permutation or Bootstrap Hypothesis Tests. American Statistician, 2002, 56, 63-70.	0.9	28
120	Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. British Journal of Haematology, 2002, 119, 97-105.	1.2	42
121	Regression analysis based on pairwise ordering of patients' clinical histories. Statistics in Medicine, 2002, 21, 3353-3367.	0.8	19
122	A Latent Autoregressive Model for Longitudinal Binary Data Subject to Informative Missingness. Biometrics, 2002, 58, 631-642.	0.8	35
123	Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. Journal of the American College of Cardiology, 2001, 37, 1093-1099.	1.2	49
124	Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood, 2001, 98, 3513-3519.	0.6	135
125	Essentials of Randomized Clinical Trials. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 254-259.	0.5	0
126	Testing for treatment and interaction effects in semi-parametric analysis of covariance. Statistics in Medicine, 2001, 20, 1-19.	0.8	3

#	ARTICLE	IF	CITATIONS
127	Electrical Storm Presages Nonsudden Death. <i>Circulation</i> , 2001, 103, 2066-2071.	1.6	346
128	Modeling Repeated Count Data Subject to Informative Dropout. <i>Biometrics</i> , 2000, 56, 667-677.	0.8	59
129	Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 2402-2410.	1.8	3,201
130	Predictors of Mortality and Mortality From Cardiac Causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry. <i>Circulation</i> , 2000, 101, 2682-2689.	1.6	119
131	On the Effect of Treatment among Would-Be Treatment Compliers: An Analysis of the Multiple Risk Factor Intervention Trial. <i>Journal of the American Statistical Association</i> , 2000, 95, 1101-1109.	1.8	44
132	Use of Summary Measures to Adjust for Informative Missingness in Repeated Measures Data with Random Effects. <i>Biometrics</i> , 1999, 55, 75-84.	0.8	33
133	Repeated Probit Regression When Covariates Are Measured With Error. <i>Biometrics</i> , 1999, 55, 403-409.	0.8	6
134	Bayesian Monitoring of Event Rates with Censored Data. <i>Biometrics</i> , 1999, 55, 603-607.	0.8	13
135	Valid Inference in Random Effects Meta-Analysis. <i>Biometrics</i> , 1999, 55, 732-737.	0.8	112
136	A Simple Permutation-Type Method for Testing Circular Uniformity with Correlated Angular Measurements. <i>Biometrics</i> , 1999, 55, 782-791.	0.8	7
137	A Multivariate Test of Interaction for Use in Clinical Trials. <i>Biometrics</i> , 1999, 55, 1151-1155.	0.8	23
138	Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial. <i>Journal of the American College of Cardiology</i> , 1999, 34, 325-333.	1.2	103
139	A Restricted Test of Circadian Rhythm. <i>Journal of the American Statistical Association</i> , 1997, 92, 717-724.	1.8	2
140	A New Approach to Assessing Regional and Global Myocardial Contractility. <i>Echocardiography</i> , 1997, 14, 1-7.	0.3	3
141	A Simple Multivariate Test for One-Sided Alternatives. <i>Journal of the American Statistical Association</i> , 1996, 91, 854-861.	1.8	80
142	Multivariate tests for multiple endpoints in clinical trials. <i>Statistics in Medicine</i> , 1995, 14, 1163-1175.	0.8	63
143	Multiple Comparisons with Control in a Single Experiment versus Separate Experiments: Why Do We Feel Differently?. <i>American Statistician</i> , 1995, 49, 144-149.	0.9	26
144	An Approximate Generalized Linear Model with Random Effects for Informative Missing Data. <i>Biometrics</i> , 1995, 51, 151.	0.8	231

#	ARTICLE	IF	CITATIONS
145	Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. <i>Journal of Pediatrics</i> , 1995, 127, 137-146.	0.9	126
146	The effect of estimation and biasing strategies on selection bias in clinical trials with permuted blocks. <i>Journal of Statistical Planning and Inference</i> , 1994, 39, 1-17.	0.4	13
147	Gender differences in the psychosocial variance of Framingham and Bortner type a measures. <i>Journal of Psychosomatic Research</i> , 1993, 37, 709-716.	1.2	7
148	Variance imputation for overviews of clinical trials with continuous response. <i>Journal of Clinical Epidemiology</i> , 1992, 45, 769-773.	2.4	1,137
149	The use of subjective rankings in clinical trials with an application to cardiovascular disease. <i>Statistics in Medicine</i> , 1992, 11, 427-437.	0.8	41
150	Identifiability of finite mixtures of logistic regression models. <i>Journal of Statistical Planning and Inference</i> , 1991, 27, 375-381.	0.4	49
151	Personal characteristics, unemployment insurance, and the duration of unemployment. <i>Journal of Econometrics</i> , 1990, 45, 351-366.	3.5	10
152	Learning Curves, Personal Characteristics, and Job Performance. <i>Journal of Labor Economics</i> , 1989, 7, 129-146.	1.5	24
153	Generalizing Logistic Regression by Nonparametric Mixing. <i>Journal of the American Statistical Association</i> , 1989, 84, 295-300.	1.8	106
154	Consistent estimation in the rasch model based on nonparametric margins. <i>Psychometrika</i> , 1988, 53, 553-562.	1.2	49
155	Distinguishing Heterogeneity From Decreasing Hazard Rates. <i>Technometrics</i> , 1988, 30, 389-396.	1.3	35
156	Branching process models to identify risk factors for infectious disease transmission. <i>Journal of Computational and Graphical Statistics</i> , 0, , 1-29.	0.9	1